Literature DB >> 1356633

Monoclonal antibodies targeting murine LFA-1 induce LFA-1/ICAM-1-independent homotypic lymphocyte aggregation.

R P Wuthrich1.   

Abstract

We have identified three anti-murine LFA-1 alpha monoclonal antibodies (M17/4.2, G-48, and FD441.8) which are capable of inducing homotypic aggregation of murine T cell lines (3A9 EL-4 cells). The LFA-1-induced aggregation is temperature-dependent, necessitates metabolic energy, and requires an intact cytoskeleton, but is independent of transcription and protein synthesis. The aggregation is inhibited in Ca2+ and Mg2+ free media and is also blocked with EDTA and EGTA. The aggregation does not involve protein kinase A or C or changes in intracellular calcium. The LFA-1 alpha-induced homotypic aggregation is inhibited with LFA-1 beta antibodies, but not with antibodies targeting ICAM-1, VCAM-1, VLA-4, or CD2. 3A9 cells do not express the LFA-1 ligand ICAM-1, whereas EL-4 cells express moderate amounts of ICAM-1. Thus, targeting LFA-1 alpha with mAb results in homotypic aggregation of T cell lines which is independent of ICAM-1/LFA-1 interactions, but may involve other LFA-1 ligands such as ICAM-2 or ICAM-3. Alternatively, LFA-1 may function as a signaling molecule, triggering other yet to be defined adhesion molecules to interact.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356633     DOI: 10.1016/0008-8749(92)90222-b

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  2 in total

1.  ICAM-1-, -2- and LFA-1-independent homotypic T cell aggregation induced by a novel activating monoclonal antibody targeting the murine Thy-1 molecule.

Authors:  X Fan; P Benz; R P Wüthrich
Journal:  Inflammation       Date:  1996-08       Impact factor: 4.092

2.  CD4+ T Cell Fate Decisions Are Stochastic, Precede Cell Division, Depend on GITR Co-Stimulation, and Are Associated With Uropodium Development.

Authors:  Stephen P Cobbold; Elizabeth Adams; Duncan Howie; Herman Waldmann
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.